申请人:Nyegaard & Co. A/S
公开号:US04399140A1
公开(公告)日:1983-08-16
Compounds of the formula: ##STR1## wherein X represents a halogen atom; R.sup.1 and R.sup.2, which may be same or different, each represents a hydrogen atom, or a C.sub.1-4 alkyl group; Het represents a C-attached 3-9 membered, saturated, unsaturated or aromatic heterocyclic ring containing one or more hetero atoms selected from O, N and S and optionally carrying a fused ring and/or optionally substituted by one or more substituents selected from halogen atoms and hydroxy, C.sub.1-4 alkoxy, amino, acylamino, nitro, oxo, C.sub.1-4 alkyl groups and monocyclic carbocyclic and heterocyclic aryl groups having 5 to 8 ring members; such a heterocyclic ring being saturated and having only a single heteroatom when there are 3 or 4 ring members; and alk represents a C.sub.1-4 saturated or unsaturated, straight or branched chain, divalent aliphatic hydrocarbyl group optionally substituted by one or more groups selected from carbocyclic aryl groups and heterocyclic groups as defined for Het above, and the salts thereof have been found to possess metaphase arresting ability which by virtue of its reversibility is of use in combating abnormal cell proliferation. Thus a knowledge of the cell division cycles of the normal and abnormal cells enables a cytotoxic drug to be administered while the abnormal cells are in a phase susceptible to attack and while the normal cells are in a non-susceptible phase. The compounds of the invention are prepared by alkylation, ring closure of the pyrimidine ring, halogenation or ring closure of the heterocyclic ring Het.
该公式的化合物:##STR1## 其中X代表卤素原子;R.sup.1和R.sup.2,可以相同也可以不同,分别代表氢原子或C.sub.1-4烷基;Het代表一个C-连接的3-9成员、饱和、不饱和或芳香杂环环,其中包含一个或多个从O、N和S中选择的杂原子,且可选择携带一个融合环和/或可选择由一个或多个卤素原子和羟基、C.sub.1-4烷氧基、氨基、酰胺基、硝基、氧代、C.sub.1-4烷基和单环碳环和具有5到8个环成员的杂环芳基基团中的一个或多个取代基;当有3或4个环成员时,这样的杂环环是饱和的,只有一个杂原子;而alk代表一个C.sub.1-4饱和或不饱和、直链或支链的二价脂肪族烃基,可选择由一个或多个如上所定义的碳环芳基基团和杂环基团取代,并且它们的盐已被发现具有中期阻滞能力,由于其可逆性,因此可用于对抗异常细胞增殖。因此,对正常和异常细胞的细胞分裂周期的了解使得可以在异常细胞处于易受攻击的阶段而正常细胞处于不易受攻击的阶段时给予细胞毒性药物。该发明的化合物通过烷基化、嘧啶环的环闭合、卤代或杂环环Het的环闭合制备。